Sangamo BioSciences (SGMO)

Company Description

Sangamo BioSciences is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase II clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. SGMO’s other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington’s disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. SGMO’s core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington’s disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation.

 

COMPANY ADDRESS
501 Canal Boulevard
Richmond, California 94804
United States

COMPANY PHONE
510-970-6000

COMPANY WEBSITE



Get BioInvest's perspective on Sangamo's CEO


Latest Company News

Sangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference ... Yahoo Finance - 16 hours ago 21, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), the leader in therapeutic genome editing, announced today that the company will release its fourth quarter and full year 2016 financial results before the market opens on Tuesday, February 28, ... [...]
Tue, Feb 21, 2017 9:09:00 PM, Continue reading at the source
Stock Returns: Rigel Pharmaceuticals Inc (NASDAQ:RIGL) versus Sangamo ... CML News - Feb 21, 2017 This is a snapshot to compare the stock returns for Rigel Pharmaceuticals Inc (NASDAQ:RIGL) versus Sangamo Therapeutics Inc (NASDAQ:SGMO) . The stock return points we compare look at the last three-months, six-months and twelve-months. At the end ... [...]
Tue, Feb 21, 2017 12:11:00 PM, Continue reading at the source
Option Trading: Sangamo Therapeutics Inc (NASDAQ:SGMO) Winning Long Put ... CML News - Feb 19, 2017 We're going to look at a wonderful result using long put spreads for Sangamo Therapeutics Inc by pinpointing earnings risk, and then navigating around it. [...]
Sun, Feb 19, 2017 9:11:00 PM, Continue reading at the source
Sangamo Therapeutics Inc Stock Volatility Hits A Notable High CML News - Feb 17, 2017 This is a proprietary realized volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for Sangamo Therapeutics Inc (NASDAQ:SGMO) . We examine the little used gem of daily stock volatility over a ... [...]
Fri, Feb 17, 2017 2:51:00 PM, Continue reading at the source
Stock Returns: Sangamo Therapeutics Inc (NASDAQ:SGMO) versus Vanda ... CML News - Feb 16, 2017 This is a snapshot to compare the stock returns for Sangamo Therapeutics Inc (NASDAQ:SGMO) versus Vanda Pharmaceuticals Inc (NASDAQ:VNDA) . [...]
Thu, Feb 16, 2017 2:48:00 PM, Continue reading at the source
Sangamo Therapeutics Announces Upcoming Presentations At The 13th Annual ... Yahoo Finance - Feb 8, 2017 RICHMOND, Calif., Feb. 8, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), the leader in therapeutic genome editing, today announced upcoming oral and poster presentations at the 13th Annual WORLDSymposium™ Meeting being held in San ... [...]
Wed, Feb 08, 2017 9:00:00 PM, Continue reading at the source
Sangamo Therapeutics Inc Risk Points versus Health Care CML News - Feb 3, 2017 This is a scatter plot analysis of the critical risk points from the option market for Sangamo Therapeutics Inc (NASDAQ:SGMO) compared to its own past and the Health Care ETF. [...]
Fri, Feb 03, 2017 6:56:00 PM, Continue reading at the source
Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 ... PR Newswire (press release) - Jan 11, 2017 RICHMOND, Calif., Jan. 11, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the U.S. [...]
Wed, Jan 11, 2017 12:31:00 PM, Continue reading at the source
Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus ... PR Newswire (press release) - Jan 6, 2017 RICHMOND, Calif., Jan. 6, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announces that it has changed its corporate name, from "Sangamo BioSciences, Inc." to "Sangamo Therapeutics, Inc." ... [...]
Fri, Jan 06, 2017 1:06:00 PM, Continue reading at the source
Sangamo Therapeutics Inc. MarketWatch - Dec 21, 2009 Check out the returns on our 8 Lazy Portfolios that are made up of low-cost buy-and-hold index funds. • How to create your own Lazy Portfolio. [...]
Mon, Dec 21, 2009 8:58:00 PM, Continue reading at the source